Bexion Pharmaceuticals, Inc. to Present at the 25th Annual Meeting of Future Leaders in the BioTech Industry

FOR IMMEDIATE RELEASE [Covington, KY ~ February 14, 2018] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that Dr. Ray Takigiku, Founder and CEO of the Company will present an overview and recent advancements of its lead compound, BXQ-350 at the Future Leaders in the BioTech Industry ... Read More

Bexion Pharmaceuticals Honoree at American Cancer Society Annual Ball

COVINGTON, KY. November 16, 2016 – Bexion Pharmaceuticals was awarded the “Medical Professional Award” at the American Cancer Society’s Annual Striders’ Ball held on November 5, 2016. This is the first time the honor has been bestowed on a company versus an individual medical professional. “We are greatly honored to have been nominated, and to ... Read More

Bexion Pharmaceuticals Doses First Patient in Phase I Trial of BXQ-350 For Patients with Advanced Solid Tumors at the University of Cincinnati Cancer Institute

FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY. September 20, 2016- Bexion Pharmaceuticals, LLC (‘Bexion”) and the University of Cincinnati Cancer Institute (UCCI) announced today the dosing of the first patient in the Phase I trial of BXQ-350, a novel anti-cancer therapeutic agent. This open-label trial will include adult patients with advanced solid ... Read More

Bexion Pharmaceuticals and CTI Clinical Trial and Consulting Services Announce Collaboration on First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

FOR IMMEDIATE RELEASE [Cincinnati, OH ~ September 8, 2016] Bexion Pharmaceuticals (Bexion) and CTI Clinical Trial and Consulting Services (CTI) announce their collaboration on the First-in-Human Phase I clinical trial with BXQ-350 for the treatment of cancer. The FDA recently cleared Bexion’s application to initiate the open-label trial that will include adult patients with advanced ... Read More

Bexion Pharmaceuticals Receives FDA Clearance For the First Clinical Trial Using BXQ-350 to Dose Patients with Cancer

FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY, July 18, 2016- Bexion Pharmaceuticals, LLC (‘Bexion”) announced today that the U.S. Food and Drug Administration (FDA) cleared Bexion’s application to initiate a First-in-Human Phase I clinical trial with BXQ-350 for the treatment of cancer. This open-label trial will include adult patients with advanced solid ... Read More

Bexion Pharmaceuticals Wins 2015 Tibbetts Award From the Small Business Administration

FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY, June 1, 2015 -- Bexion Pharmaceuticals LLC announced that the Small Business Administration (SBA) has awarded the Company the prestigious Tibbetts Award, recognizing Bexion as a “Model of Excellence” for the Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Awarded ... Read More

Bexion Pharmaceuticals Receives Orphan Drug Designation for Saposin C, the Active Ingredient in BXQ-350 for Glioblastoma Multiforme from FDA

FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY, Feb. 16, 2015 -- Bexion Pharmaceuticals LLC announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for Saposin C, active  ingredient in its proprietary drug BXQ-350 for the potential treatment of glioblastoma multiforme. The FDA’s Office of ... Read More